间充质干细胞
间质细胞
基因
基因表达
血管瘤
医学
病理
生物
癌症研究
生物信息学
遗传学
作者
Carlotta Abbà,Stefania Croce,Chiara Valsecchi,Elisa Lenta,Rita Campanelli,Alessia Claudia Codazzi,Valeria Brazzelli,Adriana Carolei,Paolo Catarsi,Gloria Acquafredda,Antonia Apicella,Laura Caliogna,Micaela Berni,Savina Mannarino,Maria Antonietta Avanzini,Vittorio Rosti,Margherita Massa
出处
期刊:Cells
[MDPI AG]
日期:2024-01-29
卷期号:13 (3): 254-254
标识
DOI:10.3390/cells13030254
摘要
We previously published that in patients with infantile hemangioma (IH) at the onset (T0) colony forming unit-fibroblasts (CFU-Fs) are present in in vitro cultures from PB. Herein, we characterize these CFU-Fs and investigate their potential role in IH pathogenesis, before and after propranolol therapy. The CFU-F phenotype (by flow cytometry), their differentiation capacity and ability to support angiogenesis (by in vitro cultures) and their gene expression (by RT-PCR) were evaluated. We found that CFU-Fs are actual circulating MSCs (cMSCs). In patients at T0, cMSCs had reduced adipogenic potential, supported the formation of tube-like structures in vitro and showed either inflammatory (IL1β and ESM1) or angiogenic (F3) gene expression higher than that of cMSCs from CTRLs. In patients receiving one-year propranolol therapy, the cMSC differentiation in adipocytes improved, while their support in in vitro tube-like formation was lost; no difference was found between patient and CTRL cMSC gene expressions. In conclusion, in patients with IH at T0 the cMSC reduced adipogenic potential, their support in angiogenic activity and the inflammatory/angiogenic gene expression may fuel the tumor growth. One-year propranolol therapy modifies this picture, suggesting cMSCs as one of the drug targets.
科研通智能强力驱动
Strongly Powered by AbleSci AI